- Premium Stock Alerts
- Posts
- Unlock Profits Before the Bell Rings! Pre-Market Intel Inside
Unlock Profits Before the Bell Rings! Pre-Market Intel Inside
Noor Saba
May 08, 2024
Don’t want emails from us anymore? Click here to unsubscribe
Hello Part-time Trader…👋
Premium Stock Alerts is here with your pre-market cheat sheet. In today's issue, we delve into:
Fed's Latest Announcements: Understand the Federal Reserve's recent decisions and economic outlook, and how they might influence the markets.
Volume Anomalies: Identify stocks witnessing unusual trading volumes, pointing to potential opportunities or risks.
Top Pre-Market Movers: Identify early winners poised for a strong market opening.
Market Indices & Sector Overview: Get a snapshot of key market indices and sector performances to gauge the day's potential trends.
FDA Approvals & Upcoming Decisions: Keep an eye on the latest FDA approvals and crucial upcoming decisions affecting biotech and pharmaceutical stocks.
Now, let's dive into today's edition for a closer look at the insights and analysis that will shape your trading decisions.
Sponsored
The Next Nvidia?
Wall Street legend has just uncovered one tiny Maryland company that could become the next Nvidia.
Few in the media are talking about this story yet... but in the next 6 months that's all they'll talk about.
Go here now for this breaking story.
Happening Today
✓ 10:00 AM ET – Wholesale inventories
✓ 10:30 AM ET – Crude Oil Inventories
✓ 11:00 AM ET – Fed Vice Chair Philip Jefferson speaks
✓ 11:45 AM ET – Boston Fed President Susan Collins speaks
✓ 01:30 PM ET – Fed Gov. Cook speaks
PREMARKET SNAPSHOT 📈
U.S. stock futures trade slightly higher ahead of the opening bell, with the S&P500 leading the gains.
S&P500$5187.7 ⬆️ 0.13% | Dow$38884.26 ⬆️ 0.08% | NASDAQ$18091.445 ⬇️ -0.01% |
SECTOR SNAPSHOT ✨
Mixed market with Materials (1.17%) and Utilities (1.12%) leading the gains, while Consumer Discretionary (-0.56%) and Information Technology (-0.53%) lagging behind.
NAME | PRICE | %CHANGE |
|---|---|---|
Consumer Discretionary | 1,460.52 | -0.56% 🔴 |
Consumer Staples | 819.10 | +1.09% 🟢 |
Energy | 711.59 | -0.14% 🔴 |
Financials | 684.69 | +0.32% 🟢 |
Health Care | 1,661.01 | +0.81% 🟢 |
Industrials | 1,051.98 | +0.24% 🟢 |
Materials | 573.86 | +1.17% 🟢 |
Real Estate | 234.48 | +1.07% 🟢 |
Information Technology | 3,770.16 | -0.53% 🔴 |
Communication Services | 292.14 | +0.57% 🟢 |
Utilities | 352.84 | +1.12% 🟢 |
Sponsored
NOW is the time to get in on this trillion-dollar megatrend
Now is the time to position yourself for the next round of explosive growth from what will soon be a trillion-dollar market. But don't chase yesterday's winners!
The AI hype is off the charts and some AI stocks have run so far that they are looking WAY overvalued. When they crash back down to earth, some investors could get hurt. I don't want that to happen to you! So I'm making our new special report on the best AI stocks to own now free for a limited time.
Get it here.
Unusual Volume
📈 Nuwellis Inc (NUWE) jumped 54.04% to $0.26 on a whopping 134.35 million shares traded after it announced first quarter 2024 financial results.
📈 Investors went wild, sending Vistra Corp (VST) stock declining -1.80% to $81.74 on a massive volume of 86.26 million shares.
📈 Abnormal activity shook Peloton Interactive Inc (PTON), pushing it up 15.54% to $4.09 on a whopping 59.16 million shares traded.
📈 Walt Disney Co (DIS) stock recently closed -9.51% lower at $105.39 on substantial volume of 54.82 million shares after reporting earnings for its second quarter ended March 30, 2024.
📈 Clearmind Medicine Inc (CMND) increase by 26.50% in a single trading session, with abnormally high trading volume of 49.42 million shares following the signing of an exclusive patent licensing agreement with Yissum Research Development Company of the Hebrew University of Jerusalem.
Sponsored
FREE Investor Report: Zacks' 7 Best Stocks for May
Since 1988, Zacks' objective, mathematical stock prediction system has beaten the market consistently and convincingly.
This just-released Special Report reveals the 7 most explosive stocks from the list of current Zacks Rank #1 Strong Buys.
Less than 5% of stocks meet the criteria to be one of our "7 Best." Discover these recommended stock picks before your next trade.
Download it here, absolutely FREE
Premarket Movers
Enveric Biosciences, Inc. (ENVB) experiences a substantial 20.22% surge in pre-market trading after announcing that it has signed a non-binding term sheet with an undisclosed biotechnology development and commercialization company.
Clover Health Investments, Corp. (CLOV) sees a significant 16.07% increase, reaching a pre-market price of $0.85 after reporting financial results for the first quarter 2024.
Repare Therapeutics Inc. (RPTX) demonstrates a noteworthy 20.42% surge, with a pre-market price of $3.95. The company reported financial results for the first quarter ended March 31, 2024.
Pre Market Gainers | Pre Market Change | Pre Market Volume |
|---|---|---|
ISUN | +44.85% | 12.18M |
ENVB | +20.22% | 4.24M |
LAZR | +6.06% | 1.94M |
NCI | +16.99% | 1.75M |
RPTX | +20.42% | 586.51K |
CLOV | +16.07% | 524.45K |
HSDT | +6.11% | 304.00K |
LYFT | +5.42% | 228.11K |
ASTI | +4.25% | 138.49K |
AFRM | +5.36% | 109.66K |
Sponsored
Invest in the Autoimmune Revolution: Next-Gen Therapy
Seize the opportunity to invest in groundbreaking autoimmune solutions. This Company is leading the charge with a novel therapy that promises to transform patient lives and disrupt the autoimmune market.
Stand with us as we navigate this uncharted territory, offering robust returns and the chance to make a profound impact on healthcare. Your investment fuels the future of medicine.
Click here to delve deeper into this thrilling investment opportunity.
Important FDA
Recently Announced
Day One Biopharmaceuticals (DAWN) is celebrating a significant achievement with the FDA's endorsement of their drug Tovorafenib, now marketed as OJEMDA. This medicine brings renewed optimism to children contending with a specific form of brain tumor: relapsed or progressive pediatric low-grade glioma.
X Pharmaceuticals (XFOR) can also raise a toast as their drug Mavorixafor, rebranded as XOLREMDI, has gained the FDA's approval. This medication introduces a fresh approach to addressing WHIM syndrome, a rare and challenging condition affecting individuals aged twelve and above.
Neurocrine Biosciences Inc (NBIX) has broadened the accessibility of their existing medication, Ingrezza. The FDA recently gave the nod to a new sprinkle formulation, enhancing convenience for adults managing tardive dyskinesia and chorea associated with Huntington's disease.
Upcoming Announcements
May 9th: Pfizer (PFE) anxiously awaits the FDA's decision on their full approval application (sBLA) for Tivdak in the treatment of a specific type of recurrent or metastatic cervical cancer. Tivdak currently holds only accelerated approval.
May 12th: The spotlight shines on Moderna, Inc (MRNA) as the FDA evaluates their BLA for mRNA-1345, a vaccine designed to combat the respiratory syncytial virus (RSV). This vaccine has the potential to revolutionize public health.
May 13th: Dynavax Technologies Corp (DVAX) anticipates positive news from the FDA regarding their BLA for HEPLISAV-B, a hepatitis B vaccine. This application aims to broaden the vaccine's usage to include adults undergoing hemodialysis, a demographic highly susceptible to the disease.
🎁 Looking for More? Check out these complementary newsletters for diverse perspectives:
|
|
|
Happy investing,
Maeve Grace
Editor In Chief
Premium Trade Alerts
Important: This newsletter does not provide investment advice. The stocks mentioned should not be taken as recommendations. Your investments are solely your decisions.
Disclosure: I hold no positions in any companies mentioned, either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I have no business relationship with any company whose stock is mentioned in this article.
Reply